valu usd unless otherwis note
pharmaceut segment look end
high note thought
view pharma becom growth engin sale
five mega-blockbust manag highlight
may investor day gather momentum pipelin also
progress despit setback new product indic
contribut pharma growth year rais price target
reflect shift base year valuat
rais estim base better expect
pharmaceut prescript trend rais sale forecast
 busi ww revenu
increas take ww revenu forecast
guidanc ep estim move
estim guidanc
estim segment oper growth rate
 medic devic
pharmaceut segment growth engin
optim reli jnj mega-blockbust stelara imbruvica
darzalex xarelto invega sustenna/trinza estim ww
sale five grew account jnj
ww oper revenu growth estim ww sale
five increas offset sale eros
remicad brand could face gener competit
zytiga largest ww
segment forecast impli oper growth forecast
includ eu approv tremfya fda approv apalutamid
challeng confront reviv growth medic devic
consum first nine month organ revenu growth
medic devic consum respect
busi medic devic well cardiovascular vision
two biggest product franchis orthoped surgeri
bare grow consum growth beauti over-the-counter
off-set declin other sinc end market unlik materi
improv portfolio realign divestitur
may necessari improv growth profil segment
pharmaceut segment perform suffici catalyst
need hit trifecta drive meaning stock
out-performance share gener total return
versu perform gener
strong show segment howev despit nme
approv new indic sever brand promis clinic
data share under-perform
versu observ lead us conclud
out-performance medic devic consum segment
may requir share replic success
price prior trade day market close estimate unless otherwis note
segment revenu growth rebound
organ growth least high organ
growth compar
exclud benefit pharma revenu prior
basi brand stelara imbruvica
darzalex invega sustenna xarelto drove strong
perform estim pharma growth
higher
three new product annual peak sale
billion expect win approv
time-frame tremfya approv fda last juli
treatment psoriasi await eu approv
two esketamin expect file
regulatori approv year apalutamid fda
review initi indic treatment-resist major
depress disord pre-metastat prostat cancer acut
myeloid leukemia respect also work
line extens sever could gener
million annual sale
franchis good start manag laid
four-prong growth strategi two key brand opsumit
uptravi frequent earlier use combin
regimen pah treatment improv patient respons
extend treatment durat expand usag new
patient segment broaden geograph reach
volum growth rather price increas key
increas slow channel particip continu exert
downward pressur price even absenc
legisl action innov hold key thrive
environ strong track record past
year bring breakthrough therapi market well
ahead industri averag
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part sotp price-to-earnings analysi valu three segment
medic devic consum separ
base peer group multipl base case estim
assum mid single-digit oper growth includ
low single-digit organ growth exclud
margin expans share buyback price
target impli price-to-earnings multipl ep estim
 lift revenu growth basi point
restructur portfolio ration lead superior
leverag rel base case scenario
pharmaceut price rhetor lead legisl
chang govern negoti price
price-to-earnings multipl ep estim
aggress eros remicad brand
biosimilar gener competit lack depress
revenu growth neg leverag dent
multipl downsid scenario impli
price-to-earnings multipl ep estim
price target base sum-of-the-part sotp analysi comp use
blend peer across consum pharmaceut medic devic sector price
target impli ep estim price target basi
outperform rate share
risk rate price target
face risk typic global diversifi healthcar compani includ
slump navig fda may impedi price target rate
johnson johnson one largest diversifi healthcar busi
world oper compani encompass broad rang product across
healthcar field compani world-wide busi divid three main segment
medic devic diagnost sale consum
